Neuropsychiatry Lupus

West, Sterling G.

doi:10.1016/s0889-857x(21)00229-5

Cited by 169 publications

(3 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transverse myelitis (TM), a rare but serious SLE manifestation, is characterized by an acutely progressive course of paralysis, sensory deficit, and sphincter dysfunction. The estimated incidence rate of TM is 1–2% in patients with SLE, 1 – 3 although the reported rate varies widely between studies.…”

Section: Introductionmentioning

confidence: 99%

Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus

Wang

Zhang

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Purpose: We aimed to describe the clinical characteristics and outcomes of patients with transverse myelitis (TM) as a rare manifestation in systemic lupus erythematosus (SLE) and explore the risk factors and prognosis of SLE-related TM (SLE-TM). Methods: We conducted a retrospective case–control and cohort analysis. All patients with SLE-TM (58 patients) and 232 with SLE without TM, as a control group, were admitted to Peking Union Medical College Hospital between January 1993 and May 2021. Factors associated with the presence of SLE-TM and its prognosis were assessed using logistic regression and Cox proportional hazard models. Results: Multivariate analysis revealed that positive anti-Ro/Sjogren’s syndrome A (anti-Ro/ SSA) (<0.01) and increased erythrocyte sedimentation rate (ESR) ( p < 0.01) were associated with SLE-TM. Regarding prognosis, methylprednisolone (MP) pulse therapy within 2 weeks of onset (adjusted hazard ratio (AHR), 2.12; 95% confidence interval (CI), 1.06–4.23; p = 0.03) was associated with short-term neurological improvement. An American Spinal Injury Association Impairment Scale (AIS) grades of A, B, or C at onset (AHR, 0.12; 95% CI 0.05–0.28; p < 0.001) and hypoglycorrhachia (AHR, 0.29; 95% CI, 0.13–0.65; p < 0.01) were associated with a short-term non-improved outcome. Conclusions: The positive anti-Ro/SSA antibodies and increased ESR may be associated with the presence of SLE-TM. An initial presentation with severe myelitis and hypoglycorrhachia appear to be predictors of a poor neurological outcome. Early steroid pulse therapy may improve the prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus

Wang

Zhang

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…No entanto, a frequência dessas manifestações é muito variável, dependendo do tipo de manifestação incluída e do método usado para avaliação (2,19,(43)(44)(45) (65,71,83).…”

Section: Critérios Classificatórios Do Lesunclassified

Avaliação longitudinal das citocinas Th1 (TNF-'alfa', INF-'gama', IL-12) e Th2 (IL-4, IL-6, IL10) em pacientes com lúpus eritematoso sistêmico

Postal¹

View full text Add to dashboard Cite

The aim of this study was to evaluate, during the period of two years, the sera levels of Th1 cytokines and Th2 in SLE patients and healthy controls, associating these cytokines with disease activity and the different clinical and laboratory manifestations presented by SLE patients, and also, to assess whether there was a variation in the sera of Th1 and Th2 cytokines levels and if they could be considered potential biomarkers. It was an open, longitudinal study with a control group. Consecutive SLE patients followed at the Rheumatology Unit (Hospital de Clínicas/UNICAMP) were recruited. Clinical, laboratory and medication were assessed. Disease activity was determined by [SLE Disease Activity Index (SLEDAI)] and the cumulative damage by [Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)]. Sera cytokines levels were performed by Enzyme Linked Immunosorbent Assay (ELISA). Two hundred and eighteen (210 women) SLE patients, with a mean age of 42.62 years [standard deviation (SD) ±11.98 years] were included. The control group, with similar age and sex distributions consisted of 46 (40 women) healthy volunteers with a mean age of 40.04±13.54. It was observed that IL-6 remained significantly increased in SLEpatients compared to healthy controls over time. In the paired analyses, significant fluctuation in IFN-γ (p=0.026), IL-12 (p<0.001), IL-4 (p=0.001) and IL-10 (p<0.001) levels were observed. There were no significant fluctuation in the sera TNF-α and IL-6 levels. It was observed that sera IL-10 levels were associated and correlated with disease activity, at follow up. INF-γ, IL-4 and IL-10 were associated with NP manifestations in SLE patients. A significant difference was observed in the progressive loss of brain volume (p=0.028) and corpus callosum volume (p<0.001) of SLE patients compared to healthy controls. There was an association between IL-12 and progressive brain atrophy (p=0.008) and a direct correlation between sera IL-12 levels and percentage loss of brain volume (rs=0.3; p=0.015) was observed. No association between progressive brain atrophy and other cytokines or clinical and laboratory manifestations were observed. To sum up, there is a significant fluctuation in sera IFNγ, IL-12, IL-4 and IL-10 levels in SLE patients. IL-10 may be considered a biomarker for disease activity and nephritis in SLE. IFN-γ, IL-4 and IL-10 can identify patients with CNS involvement. IL-12 may be considered a biomarker for brain damage in SLE.

show abstract

“…As manifestações neuropsiquiátricas (MNP) ocorrem em até 75% dos pacientes, sendo a frequência variável, dependendo do tipo de manifestação e o método para seu diagnóstico (R. Johnson 1968;L. Costallat 1990;West 1994;Hanly et al 1992). É importante também definir,em cada paciente, se a MNP apresentada é primaria, ou seja decorrente do dano imunológico do LES ou secundária a outras situações clinicas como infecções, distúrbios metabólicos, medicamentos,etc.…”

Section: Apresentação Clínica No Les Adultounclassified

Perda auditiva neurosensorial no lúpus eritematoso sistêmico

Ferrari¹

View full text Add to dashboard Cite

antifosfolípides. Quanto aos fatores de risco para doença cardiovascular observou-se associação entre perda auditiva e níveis elevados de LDL (p=0,008), corroborando a associação entre perda auditiva e dislipidemia. Não foram observadas associações com outros fatores de risco cardiovasculares estudados como triglicérides, HDL, hipertensão arterial, glicemia de jejum e índice de massa corporal (IMC).Conclusões: Apesar de considerada incomum, perda auditiva foi observada em 16% dos nossos pacientes. Não se observou associação entre a perda auditiva e idade, tempo de doença, atividade de doença, dano e anticorpos antifosfolípides. Foi encontrada associação com níveis elevados de LDL, apontando que a presença de dislipidemia pode ser responsável por estas alterações no LES.

show abstract

Neuropsychiatry Lupus

Cited by 169 publications

References 136 publications

Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus

Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus

Avaliação longitudinal das citocinas Th1 (TNF-'alfa', INF-'gama', IL-12) e Th2 (IL-4, IL-6, IL10) em pacientes com lúpus eritematoso sistêmico

Perda auditiva neurosensorial no lúpus eritematoso sistêmico

Contact Info

Product

Resources

About